Agonist Gonadotropin-Releasing Hormone (GnRH) Versus Antagonist GnRH

Yazd Research & Clinical Center for Infertility

Status and phase: Unknown; Phase 3

Conditions: Infertility

Treatments: Drug: suprefact; Drug: ganirelix

Study type: Interventional

Funder types: Other

Identifiers

NCT00823602

1387YAZDRCCI

Details and patient eligibility

About

Literature suggests that GnRH antagonists are comparatively more often used in cycles which have an unfavorable prior prognosis, and this protocol is an ideal one for poor responder patients. Up to now, however not enough prospectives have been published to prove any beneficial effect of antagonists on the first cycle assisted reproductive technique.

This prospective study will do to evaluate the efficacy of gonadotropin releasing hormone antagonist in comparison with the standard long protocol in the first cycle of ART.

The investigators will randomize 160 patients undergoing ART for the first time . Group 1 (n=80) was stimulate with a standard long protocol and group 2 (n=80) stimulated with GnRH antagonist and then result of ART compare in two group .

Enrollment: 2 estimated patients

Sex: Female

Ages: Under 35 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• first cycle of ART
• age < 35 years
• basal FSH < 10 IU/L

Exclusion criteria

• previous IVF or ICSI, hyperprolactinemia, hyperthyroidism, hypothyroidism, uterine abnormality, severe endometriosis
• only one ovary

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

2 participants in 2 patient groups

1

Experimental group

Description:

GnRH antagonist "ganirelix" 0.25 mg fromm 6th ovarian stimulation

Treatment:

Drug: ganirelix

2

Active Comparator group

Description:

GnRH agonist, suprefact, stimulation with a standard long protocol

Treatment:

Drug: suprefact